- Abstract
- Core Tip
- Article Highlights
- Full Article with Cover (PDF)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (587)
- Timeline of Article Publication (7)
- Authors Evaluation (4)
- Article Quality Tracking (0)
- Reader Comments (1)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4526)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 26, 2022 (publication date) through May 7, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rubin SJS, Balabanis T, Gubatan J, Habtezion A. Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy. World J Clin Cases 2022; 10(6): 1787-1794 [PMID: 35317167 DOI: 10.12998/wjcc.v10.i6.1787] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i6/1787.htm |
| Number | Citing Articles |
| 1 |
Konstantinos Argyriou, Athanasios Kotsakis. Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”. World Journal of Clinical Cases 2022; 10(23): 8425-8427 doi: 10.12998/wjcc.v10.i23.8425
Abstract(431) |
Core Tip(266) |
Full Article(HTML)(982)
|
Full Article (PDF)-1726K(110)
|
Full Article (Word)-103K(118)
|
Audio-845K(1)
|
Peer-Review Report-196K(40)
|
Answering Reviewers-149K(55)
|
Times Cited (0)
|
Total Visits (3562)
|
Open
|
| 2 |
Giuseppe Losurdo, Daniele Angelillo, Nicolas Favia, Maria Chiara Sergi, Alfredo Di Leo, Giacomo Triggiano, Marco Tucci. Checkpoint Inhibitor-Induced Colitis: An Update. Biomedicines 2023; 11(5): 1496 doi: 10.3390/biomedicines11051496
|
| 3 |
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo. Revista de Gastroenterología de México 2024; 89(1): 89 doi: 10.1016/j.rgmx.2023.11.001
|
| 4 |
Wenyi Li, Zhaokun Wu, Weidong Meng, Chaoting Zhang, Mingzhen Cheng, Yuehong Chen, Yini Zou, Kejun Li, Simin Lin, Wenjun Xiong, Ying Wang, Yixiong Lin, Wenhui Ma, Weijie Zhou. Blockade of IL-6 inhibits tumor immune evasion and improves anti–PD-1 immunotherapy. Cytokine 2022; 158: 155976 doi: 10.1016/j.cyto.2022.155976
|
| 5 |
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 89 doi: 10.1016/j.rgmxen.2023.11.001
|
| 6 |
Hao Xiong, Zhu Shen. Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor. International Journal of Cancer 2024; doi: 10.1002/ijc.34940
|